Biomarkers
A special series of articles discussing challenges and opportunities in the discovery, validation and application of biomarkers.
2010
March 2012 Vol 11 No 3
Cancer biomarkers: selecting the right drug for the right patient
Gary J. Kelloff & Caroline C. Sigman
doi:10.1038/nrd3651
2010
July 2010 Vol 9 No 7
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Harald Hampel, Richard Frank, Karl Broich, Stefan J. Teipel, Russell G. Katz, John Hardy, Karl Herholz, Arun L. W. Bokde, Frank Jessen, Yvonne C. Hoessler, Wendy R. Sanhai, Henrik Zetterberg, Janet Woodcock & Kaj Blennow
doi:10.1038/nrd3115
2008
January 2008 Vol 7 No 1
Neurophysiological biomarkers for drug development in schizophrenia
Daniel C. Javitt, Kevin M. Spencer, Gunvant K. Thaker, Georg Winterer & Mihály Hajós
doi:10.1038/nrd2463
2007
April 2007 Vol 6 No 4
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas
p287 | doi:10.1038/nrd2251
April 2007 Vol 6 No 4
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Leslie M. Shaw, Magdalena Korecka, Christopher M. Clark, Virginia M.–Y. Lee and John Q. Trojanowski
p295 | doi:10.1038/nrd2176
2006
June 2006 Vol 5 No 6
Diagnostics and biomarker development: priming the pipeline
Kathryn A. Phillips, Stephanie Van Bebber and Amalia M. Issa
p463 | doi:10.1038/nrd2033
Application of intravascular ultrasound in anti-atherosclerotic drug development
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu and Steven E. Nissen
p485 | doi:10.1038/nrd2040
May 2006 Vol 5 No 5
A role for fMRI in optimizing CNS drug development
David Borsook, Lino Becerra and Richard Hargreaves
p411 | doi:10.1038/nrd2027
April 2006 Vol 5 No 4
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Stephen F. Kingsmore
p310 | doi:10.1038/nrd2006